NRG Oncology, Pittsburgh, PA
Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer Jr, Priya Rastogi, Joseph P. Costantino, James N. Atkins, John P. Crown, Jonathan Polikoff, Jean-Francois Boileau, Louise Provencher, Christopher Stokoe, Timothy D. Moore, André Robidoux, Patrick J. Flynn, Virginia F. Borges, Kathy S. Albain, Sandra M. Swain, Soonmyung Paik, Eleftherios P. Mamounas, Norman Wolmark
PURPOSE
Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in patients with HER2-negative breast cancer.
PATIENTS AND METHODSA total of 3,270 women with high-risk primary IBC were randomly assigned to CRx with or without 1 year of trastuzumab. Eligibility criteria included immunohistochemistry (IHC) score 1+ or 2+ with fluorescence in situ hybridization ratio (FISH) < 2.0 or, if ratio was not performed, HER2 gene copy number < 4.0. CRx was either docetaxel plus cyclophosphamide or doxorubicin and cyclophosphamide followed by weekly paclitaxel for 12 weeks.
RESULTSAt a median follow-up of 46 months, the addition of trastuzumab to CRx did not improve IDFS (5-year IDFS: 89.8% with CRx plus trastuzumab [CRxT] v 89.2% with CRx alone; hazard ratio [HR], 0.98; 95% CI, 0.76 to 1.25; P = .85). These findings did not differ by level of HER2 IHC expression, lymph node involvement, or hormone-receptor status. For distant recurrence-free interval, 5-year estimates were 92.7% with CRxT compared with 93.6% for CRx alone (HR, 1.10; 95% CI, 0.81 to 1.50; P = .55) and for overall survival (OS) were 94.8% with CRxT and 96.3% in CRx alone (HR, 1.33; 95% CI, 0.90 to 1.95; P = .15). There were no unexpected toxicities from the addition of trastuzumab to CRx.
CONCLUSIONThe addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2–overexpressing IBC. Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.
Journal of Clinical Oncology
First Author: Emad A. Rakha
Publish Date: May 20, 2008
Journal of Clinical Oncology
First Author: Stephen E. Jones
Publish Date: Dec 1, 2006
Journal of Clinical Oncology
First Author: Edith A. Perez
Publish Date: Aug 9, 2010
JCO Oncology Practice
Publish Date: Jul 1, 2015